Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0020473 (
hyperlipidemia
)
15,891
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Hyperlipidemia
is an associated complication of diabetes mellitus. The association of hyperglycemia with an alteration of lipid parameters presents a major risk for cardiovascular complications in diabetes. The present study was designed to examine the antihyperlipidemic effect of
S-allylcysteine
(
SAC
) in STZ induced diabetic rats. The levels of blood glucose, cholesterol (TC), triglycerides (TG), free fatty acids, phospholipids and fatty acid composition were estimated in the liver and kidneys of control and experimental groups of rats. Oral administration of
SAC
at a dose of 150 mg/kg bodyweight per day to STZ-induced diabetic rats for a period of 45 days resulted in a significant reduction in fasting blood glucose, TC, TG, free fatty acids, phospholipids, LDL-C, VLDL-C and elevation of HDL-C in comparison with diabetic control group. Oral administration of
SAC
to diabetic rats also decreased the concentrations of fatty acids, viz., palmitic, stearic (16:1), and oleic acid (18:1), whereas linolenic (18:3) and arachidonic acid (20:4) were elevated. The antihyperlipidemic effect of
SAC
was compared with glyclazide; a well-known antihyperglycemic drug. The result of the present study indicates that
SAC
showed an antihyperlipidemic effect in addition to its antidiabetic effect in experimental diabetes.
...
PMID:Ameliorative potential of S-allylcysteine: effect on lipid profile and changes in tissue fatty acid composition in experimental diabetes. 2121 77
